Akebia Therapeutics, Inc. - Common Stock (AKBA)
CUSIP: 00972D105
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 263,222,327
- Total 13F shares
- 123,669,076
- Share change
- +15,091,450
- Total reported value
- $337,684,321
- Put/Call ratio
- 105%
- Price per share
- $2.73
- Number of holders
- 176
- Value change
- +$36,363,104
- Number of buys
- 103
- Number of sells
- 58
Quarterly Holders Quick Answers
What is CUSIP 00972D105?
CUSIP 00972D105 identifies AKBA - Akebia Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 00972D105:
Top shareholders of AKBA - Akebia Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
|
Company |
7%
|
18,373,961
|
$66,881,218 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.6%
|
14,611,466
|
$53,185,736 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
3%
|
7,997,153
|
$29,109,637 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.3%
|
6,074,458
|
$22,115,254 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2%
|
5,339,654
|
$19,436,343 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.6%
|
4,194,427
|
$15,267,714 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.5%
|
3,934,002
|
$14,319,767 | — | 30 Jun 2025 | |
| Muneer A. Satter |
13D/G
|
Satter Muneer A |
2.6%
|
5,747,906
|
$13,105,226 | $0 | 31 Dec 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
1.1%
|
2,889,125
|
$10,516,415 | — | 30 Jun 2025 | |
| Nuveen, LLC |
13F
|
Company |
1%
|
2,708,676
|
$9,859,581 | — | 30 Jun 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1%
|
2,667,412
|
$9,709,380 | — | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.88%
|
2,317,290
|
$8,434,935 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.82%
|
2,163,499
|
$7,875,136 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.81%
|
2,135,244
|
$7,772,288 | — | 30 Jun 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
0.76%
|
2,000,000
|
$7,280,000 | — | 30 Jun 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
0.75%
|
1,985,915
|
$7,228,731 | — | 30 Jun 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.74%
|
1,950,000
|
$7,098,000 | — | 30 Jun 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.65%
|
1,714,544
|
$6,240,940 | — | 30 Jun 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.63%
|
1,652,746
|
$6,015,995 | — | 30 Jun 2025 | |
| Informed Momentum Co LLC |
13F
|
Company |
0.55%
|
1,454,328
|
$5,293,754 | — | 30 Jun 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.51%
|
1,350,185
|
$4,913,000 | — | 30 Jun 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.46%
|
1,205,128
|
$4,386,666 | — | 30 Jun 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.45%
|
1,180,759
|
$4,297,963 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.42%
|
1,110,480
|
$4,042,148 | — | 30 Jun 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.38%
|
1,001,360
|
$3,644,950 | — | 30 Jun 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.37%
|
984,512
|
$3,583,624 | — | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.34%
|
882,101
|
$3,211,056 | — | 30 Jun 2025 | |
| FMR LLC |
13F
|
Company |
0.31%
|
813,982
|
$2,962,896 | — | 30 Jun 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.3%
|
791,352
|
$2,880,521 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.28%
|
749,015
|
$2,726,415 | — | 30 Jun 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.26%
|
695,728
|
$2,532,449 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.24%
|
639,462
|
$2,327,642 | — | 30 Jun 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.23%
|
617,318
|
$2,247,038 | — | 30 Jun 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.23%
|
615,601
|
$2,240,787 | — | 30 Jun 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.2%
|
520,629
|
$1,895,090 | — | 30 Jun 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.16%
|
425,949
|
$1,550,455 | — | 30 Jun 2025 | |
| PRUDENTIAL FINANCIAL INC |
13F
|
Company |
0.16%
|
415,143
|
$1,511,121 | — | 30 Jun 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.15%
|
382,210
|
$1,391,244 | — | 30 Jun 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.14%
|
365,035
|
$1,328,716 | — | 30 Jun 2025 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.11%
|
289,528
|
$1,054,000 | — | 30 Jun 2025 | |
| Creative Planning |
13F
|
Company |
0.11%
|
283,330
|
$1,031,321 | — | 30 Jun 2025 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.1%
|
253,954
|
$924,393 | — | 30 Jun 2025 | |
| MACKENZIE FINANCIAL CORP |
13F
|
Company |
0.09%
|
248,602
|
$904,911 | — | 30 Jun 2025 | |
| Ellen Snow |
3/4/5
|
SVP, CFO and Treasurer |
—
mixed-class rows
|
743,300
mixed-class rows
|
$872,424 | — | 31 Jan 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.09%
|
238,930
|
$869,705 | — | 30 Jun 2025 | |
| Michel Dahan |
3/4/5
|
SVP, Chief Operating Officer |
—
mixed-class rows
|
896,092
mixed-class rows
|
$846,836 | — | 13 May 2024 | |
| Nicole R. Hadas |
3/4/5
|
SVP, Chief Legal Officer |
—
mixed-class rows
|
875,243
mixed-class rows
|
$820,566 | — | 13 May 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.08%
|
219,089
|
$797,484 | — | 30 Jun 2025 | |
| Walleye Capital LLC |
13F
|
Company |
0.08%
|
214,817
|
$781,934 | — | 30 Jun 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.08%
|
210,205
|
$765,146 | — | 30 Jun 2025 |
Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q3 2025
As of 30 Sep 2025,
Akebia Therapeutics, Inc. - Common Stock (AKBA) was held by
176 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
123,669,076 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, RENAISSANCE TECHNOLOGIES LLC, UBS Group AG, Qube Research & Technologies Ltd, CITADEL ADVISORS LLC, and MPM BIOIMPACT LLC.
This page lists
176
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
157
Q3 2025 holders
176
Holder diff
19
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.